To investigate the correlation between thyroid-stimulating hormone (TSH), free T3 (FT3), free T4 (FT4), thyroidstimulating hormone receptor antibody (TRAb), and pathological parameters of ovarian cancer, we selected 122 patients with ovarian cancer and 70 patients with benign ovarian tumor. The differences in the positive rates of different pathological parameters, including TSH, FT3, FT4, and TRAb, in their serum were detected and compared through highly sensitive electrochemical immunoassay. We found that the positive rates of TSH, FT3, FT4, and TRAb in serous cystadenocarcinoma were higher than those of mucinous cystadenocarcinoma and other types of ovarian cancer. Meanwhile, the positive rates of FT3 and FT4 in stage III and IV ovarian cancer were lower than those in stage I and II ovarian cancer. However, the positive rates of FT3 and FT4 in poorly differentiated ovarian cancer were higher than those in moderately differentiated and well-differentiated ovarian cancer. The serum levels of TSH, FT3, FT4, and TRAb preoperatively, postoperatively, and after four cycles of ovarian cancer were significantly different from those in the control group. Thus, we conclude that TSH, FT3, FT4, and TRAb were abnormally expressed in the serum of ovarian cancer patients. And the application of highly sensitive electrochemical immunoassay for the detection of TSH, FT3, FT4, and TRAb in serum has important clinical value in the diagnosis of ovarian cancer.
Introduction
Ovary is the organ producing estrogen and progesterone in women. Ovarian tumors can cause changes in the expression of estrogen and progesterone, which leads to the dysfunction of organs that can express estrogen and progesterone receptors. 1 Ovarian cancer is one of the most common malignant tumors in gynecology. Due to the secretive nature of ovarian anatomy, there are often no typical symptoms in the early stages. Therefore, the misdiagnosis is very easy to occur. Consequently, most patients have been diagnosed with advanced stages. 2 The 5-year survival rate of the patients diagnosed at stages III and IV of ovarian cancer will dramatically reduce when comparing with that of the patients diagnosed at stages I and II. The mortality rate of ovarian cancer is the highest in gynecologic oncology and displayed the trend to happen in younger age 3 . Hence, the prevention and treatment task are quite arduous.
The thyroid gland also belongs to the endocrine organ of the body, and the pituitary gland is the regulating center of the function of the thyroid and the ovary. Estrogen can interact with the thyroid hormone in the hypothalamus or pituitary gland. 4 Moreover, estrogen and thyroid hormones can also regulate each other by paracrine. Thyroid has a weak ability to secrete estrogen and estrogen receptor displayed. Estrogen can upregulate the expression level of thyroid estrogen receptor and stimulate the proliferation of thyroid cells. Meanwhile, the estrogen can also affect the metabolism of thyroid hormones and reduce the degradation and clearance rate of thyroid hormone-binding globulin, thus decreasing the concentrations of free T3 (FT3) and free T4 (FT4). 5 Studies have shown that there were estrogen and progesterone receptor expression in the thyroid tissue and a mutual regulatory relationship between the thyroid and the ovary existed. 6 Related studies have also demonstrated that the levels or activity of thyroidstimulating hormone (TSH), FT3, FT4, and thyroid-stimulating hormone receptor antibody (TRAb) are correlated to the occurrence, development, and transformation of thyroid diseases. However, the relationship between the activity of TSH, FT3, FT4, TRAb, and ovarian cancer are still far from well known. Through the analysis of the serum levels of TSH, FT3, FT4, and TRAb in patients with different types of ovarian cancer and benign ovarian tumor, we explored the activity of TSH, FT3, FT4, and TRAb in patients with different diseases using highly sensitive electrochemical immunoassay. Furthermore, we studied its value in the diagnosis of ovarian carcinoma.
Materials and methods

Patients
A total of 122 cases of ovarian cancer patients treated in our hospital from April 2015 to April 2017 were enrolled as the research group (ovarian cancer group). The mean age of patients in the research group was of 48.4 ± 3.5 years. Among them, 52 cases were serous cystadenocarcinoma, 50 cases were mucinous cystadenocarcinoma, and 20 were other cases. According to the international standard of FIGO, 24 cases were in stage I, 28 cases in stage II, 40 cases in stage III, and 30 cases in stage IV. Ovarian cancer patients were all diagnosed by pathological biopsy, and they were all admitted to hospital for the first time. Meanwhile, no surgery, radiotherapy, chemotherapy, and other treatments were received before admission. Besides, patients with other primary malignant tumors, liver and kidney dysfunction, and severe medical diseases were excluded. At the same time, 70 cases with benign ovarian tumor admitted to our hospital during the same period were considered as the control group. The mean age of patients in the control group was 48.1 ± 3.3 years. Among them, 20 cases have serous cystadenoma, 30 cases have mucinous cystadenoma, 14 cases have simple cyst, and 6 cases have endometriosis cyst. The informed consent was obtained from all patients if they agreed to participate in our study.
Laboratory examination
The levels of TSH, FT3, FT4, and TRAb were detected by highly sensitive electrochemical immunoassay. 7 The automatic electrochemical luminescence apparatus purchased from Roche (COBAS6000) and the Roche's supporting reagent are used strictly according to the instructions.
Statistical analysis SPSS 21
.0 was used to analyze and conduct the data. The comparison of component proportion was conducted by Chi-square test, and the mean of multiple groups was conducted by analysis of variance (ANOVA). Student-Newman-Keuls (SNK)-q test was used to compare the two groups. P < 0.05 means a significant difference.
Results
Comparison of positive rates of TSH, FT3, FT4, and TRAb in ovarian cancer with different pathological parameters
The positive rates of TSH, FT3, FT4, and TRAb in different pathological types of ovarian cancer were statistically significant. The positive rates of TSH, FT3, FT4, and TRAb in serous cystadenocarcinoma were higher than those of mucinous cystadenocarcinoma and other pathological types of ovarian cancer (Table 1 ).
The positive rates of FT3 and FT4 in stage III and IV ovarian cancer were lower than those in stage I and II ovarian cancer. There was no significant difference in the positive rates of TSH and TRAb in ovarian cancer at different pathological stages (Table 2) .
However, the positive rates of FT3 and FT4 in different pathological grades of ovarian cancer were significantly different, and the positive rates of FT3 and FT4 in poorly differentiated ovarian cancer were higher than those in moderately differentiated and well-differentiated ovarian cancer. There was no significant difference in the positive rates of TSH and TRAb between different pathological grades of ovarian cancer ( Table 3) .
Comparison of TSH, FT3, FT4, and TRAb levels in the serum of ovarian cancer before and after treatment
The serum levels of TSH, FT3, FT4, and TRAb in preoperatively, postoperatively, and after four cycles of ovarian cancer were significantly different from those in the control group. When comparing between the two groups on a pairwise basis, the preoperative serum levels of TSH, FT3, FT4, and TRAb in ovarian cancer were significantly higher than those in the control group. The serum levels of TSH, FT3, FT4, and TRAb in ovarian cancer patients before surgery, after surgery, and after four cycles of chemotherapy decreased in sequence, and the difference between groups was statistically significant (Table 4) .
Discussion
In female malignant tumors, the incidence of ovarian cancer is the second most frequent. When most patients were diagnosed with atypical symptoms such as abdominal pain, abdominal mass, vaginal bleeding, and other symptoms, 70%-75% of the patients were diagnosed as ovarian cancer at a late stage. 8 The 2-year mortality rate of stage III and IV ovarian cancer is about 70%. Globally, 140,000 patients die from ovarian cancer every year, and thus ovarian cancer poses a serious threat to women's life and health. Estrogen and progesterone deficiency caused by ovariectomy inevitably affects each system. There is a common regulatory pathway between estrogen and thyroxine at the pituitary gland and hypothalamus, to achieve mutual regulation. 9 Thyroxine can cause morphological changes and functional decline of pituitary gonadotropic cells, inhibit the secretion of pituitary gonadotropin, and weaken the regulation of ovarian function. In vitro culture of ovarian follicle cells confirmed that thyroxine could directly inhibit the differentiation and proliferation of ovarian secretory cells, and inhibit ovarian growth by inhibiting ovarian growth and differentiation. 10 Thyroid hormones can also cause degenerative changes in the ultrastructure of pituitary gonadotropic cells, leading to a decline in the endocrine function of gonadotropin cells. Estrogen can delay its clearance to increase the expression of T binding protein and acidification of saliva, and reduce the concentrations of free T and T3, thus affecting the thyroid function. 11 Moreover, estrogen can also cause the negative feedback regulation system of the thyroid gland, which leads to the proliferation of thyroid cells. 12 Our study demonstrated that the positive rates of TSH, FT3, FT4, and TRAb are correlated with ovarian cancers in different pathological types. The positive rates of TSH, FT3, FT4, and TRAb in serous cystadenocarcinoma were higher than those in mucinous cystadenocarcinoma and other pathological types of ovarian cancer. Meanwhile, the positive rates of FT3 and FT4 of ovarian cancer in different pathological stages were also statistically significant. The positive rates of FT3 and FT4 in stage III and IV ovarian cancer were lower than those in stage I and II ovarian cancer.
The diagnostic value of thyroid hormone levels, including TSH, FT3, FT4, and TRAb, lies in the significant change in the specificity or content of thyroid hormones. Comparing with the benign ovarian lesions, the serum levels of TSH, FT3, FT4, and TRAb in patients with ovarian cancer increased to varying degrees. In the meantime, with the progress of treatment, the serum levels of TSH, FT3, FT4, and TRAb in patients with ovarian cancer were reduced to varying degrees after surgery and after four cycles of chemotherapy.
In conclusion, TSH, FT3, FT4, and TRAb are abnormally expressed in the serum of patients with ovarian cancer. Highly sensitive electrochemical immunoassay for the serum levels of TSH, FT3, FT4, and TRAb has important clinical value in the diagnosis and treatment of ovarian cancer. In addition, the sensitivity, precision, and accuracy of high-sensitivity electrochemical immunoassay are superior to those of traditional radioimmunoassay and enzyme-linked immunosorbent assay (ELISA). Determination of the serum levels of TSH, FT3, FT4, and TRAb by high-sensitive electrochemical immunoassay is helpful for the diagnosis of ovarian cancer.
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